C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Exenatide extended release for injectable suspension (Bydureon™) |
08/06/2012 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Liraglutide (VICTOZA®) |
05/01/2010 |
N/A |
Acceptable Evidentiary Criteria Available |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Golimumab (SIMPONI®) |
05/01/2010 |
N/A |
Presumption of Long-Term Non-Acute Administration |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Tesamorelin (EgriftaTM) |
06/04/2011 |
N/A |
Presumption of Long-Term Non-Acute Administration |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Anakinra (Kineret™) 100 mg |
04/13/2003 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Exenatide injection (Byetta®) |
01/19/2006 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Peginterferon alpha 2a (Pegasys® Pegasys® Proclick™) |
03/05/2006 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Peginterferon alfa-2b (SylatronTM) |
05/19/2012 |
N/A |
Presumption of Long-Term Non-Acute Administration |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Pasireotide (SIGNIFOR®) |
06/17/2013 |
N/A |
Presumption of Long-Term Non-Acute Administration |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Dulaglutide (Trulicity™) |
09/28/2015 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Methotrexate Injection (Otrexup™) |
09/28/2015 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Peginterferon beta-1a (PLEGRIDY®) |
09/28/2015 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Cosentyx® (secukinumab) |
09/28/2015 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Albiglutide for SQ injection (Tanzeum™) 30mg |
12/01/2014 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Interferon beta 1a, 1 mcg (Rebif®) |
01/01/2014 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Myalept® Metreleptin for injection 11 mg
|
10/13/2014 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Alirocumab (Praluent®) |
01/18/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Evolocumab (Repatha™) |
01/18/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Parathyroid hormone (Natpara®) |
01/18/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Asfotase alfa (Strensiq™) |
05/23/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
TriMix |
10/31/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
pegylated interferon alfa-2b) (PegIntron®) |
10/31/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Saxenda® (Liraglutide) |
10/31/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Somavert® (Pegvisomant) |
10/31/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Symlin® (Pramlintide Acetate Injection) |
10/31/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Toujeo® (Insulin glargine injection) |
10/31/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Taltz™ (Ixekizumab) |
10/31/2016 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Siliq™ (brodalumab) |
11/16/2017 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Amjevita™ (adalimumab-atto) |
11/16/2017 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Dupixent® (dupilumab) |
11/16/2017 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Erelzi™ (etanercept-SZZS) |
11/16/2017 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Kynamro®, (Mipomersen sodium)
|
11/16/2017 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Quad-Mix |
11/16/2017 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Rasuvo® (methotrexate, injection for subcutaneous use) |
11/16/2017 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Tymlos™ (abaloparatide) |
12/02/2019 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Kevzara® (sarilumab) |
12/02/2019 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Ozempic® (semaglutide) |
12/02/2019 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Aimovig® (erenumab-aooe) |
12/02/2019 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Lantus® (insulin glargine injection) |
12/02/2019 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Emgality® (galcanezumab-gnlm) |
12/02/2019 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Cyltezo™ (adalimumab-adbm) |
12/02/2019 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Besremi® (ropeginterferon alfa-2b, injection for subcutaneous use) |
06/06/2022 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Skyrizi™ (risankizumab-rzaa, injection for subcutaneous use)* |
06/06/2022 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Sogroya® (Somapacitan-beco, injection for subcutaneous use) |
06/06/2022 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Kesimpta* (ofatumumab, injection for subcutaneous use) |
09/19/2022 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Adbry™ (tralokinumab-Idrm) |
11/14/2022 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Mounjaro™ (tirzepatide) |
03/27/2023 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
IDACIO® (adalimumab-aacf) |
06/25/2023 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
ABRILADA (adalimumab-afzb) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
HADLIMA (adalimumab-bwwd) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
HULIO® (adalimumab-fkjp) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
HYRIMOZ (adalimumab-adaz) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
YUSIMRY (adalimumab-aqvh) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Entyvio (vedolizumab) |
01/14/2024 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
YUFLYMA (adalimumab-aaty) |
01/14/2024 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Wegovy (Semaglutide) |
06/30/2024 |
N/A |
Apparent on its Face |
C9399 |
UNCLASSIFIED DRUGS OR BIOLOGICALS |
Zepbound (Tirzepatide) |
06/30/2024 |
N/A |
Apparent on its Face |
J0129 |
INJECTION, ABATACEPT, 10 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED) |
Orencia®, subcutaneous use* |
11/16/2017 |
N/A |
Apparent on its Face |
J0135 |
INJECTION, ADALIMUMAB, 20 MG |
Humira® |
09/20/2005 |
N/A |
Apparent on its Face |
J0270 |
INJECTION, ALPROSTADIL, 1.25 MCG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED) |
Caverject, Prostaglandin E1 |
11/29/2002 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J0275 |
ALPROSTADIL URETHRAL SUPPOSITORY (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED) |
Muse™ |
10/31/2016 |
N/A |
Apparent on its Face |
J0364 |
INJECTION, APOMORPHINE HYDROCHLORIDE, 1 MG |
Apokyn |
11/16/2017 |
N/A |
Apparent on its Face |
J0490 |
INJECTION, BELIMUMAB, 10 MG |
Benlysta
(belimumab)
subcutaneous use*
|
12/02/2019 |
N/A |
Apparent on its Face |
J0593 |
INJECTION, LANADELUMAB-FLYO, 1 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF-ADMINISTERED) |
Takhzyro® (lanadelumab-flyo) |
12/02/2019 |
N/A |
Apparent on its Face |
J0599 |
INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), (HAEGARDA), 10 UNITS |
HAEGARDA, subcutaneous use |
01/01/2019 |
N/A |
Apparent on its Face |
J0630 |
INJECTION, CALCITONIN SALMON, UP TO 400 UNITS |
Miacalcin, Calcimar, Calcitonin-salmon |
12/26/2011 |
N/A |
Apparent on its Face |
J0801 |
INJECTION, CORTICOTROPIN (ACTHAR GEL), UP TO 40 UNITS |
Acthar Gel, subcutaneous use* |
10/01/2023 |
N/A |
Apparent on its Face |
J0802 |
INJECTION, CORTICOTROPIN (ANI), UP TO 40 UNITS |
Purified Cortrophin Gel, subcutaneous use* |
10/01/2023 |
N/A |
Apparent on its Face |
J1324 |
INJECTION, ENFUVIRTIDE, 1 MG |
Fuzeon™ |
11/26/2004 |
N/A |
Apparent on its Face |
J1438 |
INJECTION, ETANERCEPT, 25 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED) |
Enbrel® |
12/20/1999 |
N/A |
Apparent on its Face |
J1595 |
INJECTION, GLATIRAMER ACETATE, 20 MG |
Copaxone®, Glatopa® |
04/12/2003 |
N/A |
Apparent on its Face |
J1628 |
INJECTION, GUSELKUMAB, 1 MG |
Tremfya® (guselkumab) |
06/06/2022 |
N/A |
Acceptable Evidentiary Criteria Available |
J1744 |
INJECTION, ICATIBANT, 1 MG |
Icatibant (Firazyr®) |
05/19/2012 |
N/A |
Apparent on its Face |
J1748 |
INJECTION, INFLIXIMAB-DYYB (ZYMFENTRA), 10 MG |
ZymfentraTM (infliximab-dyyb) |
09/01/2024 |
N/A |
Apparent on its Face |
J1811 |
INSULIN (FIASP) FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITS |
Fiasp® for insulin pump |
09/03/2023 |
N/A |
Apparent on its Face |
J1812 |
INSULIN (FIASP), PER 5 UNITS |
Fiasp® injection* |
09/03/2023 |
N/A |
Apparent on its Face |
J1813 |
INSULIN (LYUMJEV) FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITS |
Lyumjev® for insulin pump |
09/03/2023 |
N/A |
Apparent on its Face |
J1814 |
INSULIN (LYUMJEV), PER 5 UNITS |
Lyumjev® injection* |
09/03/2023 |
N/A |
Apparent on its Face |
J1815 |
INJECTION, INSULIN, PER 5 UNITS |
Humalog®, Humulin®, Lantus®, Levemir®, Novolin®, Novolog® |
08/01/2002 |
N/A |
Apparent on its Face |
J1817 |
INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP) PER 50 UNITS |
Humalog®, Humulin®, Novolin®, Novolog®, Insulin Lispro®, Apidra Solostar® |
04/30/2009 |
N/A |
Apparent on its Face |
J1826 |
INJECTION, INTERFERON BETA-1A, 30 MCG |
Avonex® |
06/06/2022 |
N/A |
Apparent on its Face |
J1830 |
INJECTION, INTERFERON BETA-1B, 0.25 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED) |
Betaseron®, Extavia® |
04/19/1999 |
N/A |
Apparent on its Face |
J1941 |
INJECTION, FUROSEMIDE (FUROSCIX), 20 MG |
Furoscix® injection |
09/03/2023 |
N/A |
Apparent on its Face |
J2170 |
INJECTION, MECASERMIN, 1 MG |
Increlex |
10/31/2016 |
N/A |
Apparent on its Face |
J2212 |
INJECTION, METHYLNALTREXONE, 0.1 MG |
Relistor® |
04/20/2009 |
N/A |
Apparent on its Face |
J2267 |
INJECTION, MIRIKIZUMAB-MRKZ, 1 MG |
OmvohTM (mirikizumab-mrkz)* |
07/01/2024 |
N/A |
Apparent on its Face |
J2354 |
INJECTION, OCTREOTIDE, NON-DEPOT FORM FOR SUBCUTANEOUS OR INTRAVENOUS INJECTION, 25 MCG |
Sandostatin, subcutaneous use* |
10/31/2016 |
N/A |
Apparent on its Face |
J2940 |
INJECTION, SOMATREM, 1 MG |
Protropin |
11/29/2002 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J2941 |
INJECTION, SOMATROPIN, 1 MG |
Genotropin®, Humatrope®, Norditropin®, Nutropin®, Omnitrope®, Saizen®, Serostim®, Zomacton™, Zorbtive® |
12/20/1999 |
N/A |
Apparent on its Face |
J3030 |
INJECTION, SUMATRIPTAN SUCCINATE, 6 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF ADMINISTERED) |
Imitrex, Sumavel® Dosepro®, Zembrace™ |
11/29/2002 |
N/A |
Apparent on its Face |
J3031 |
INJECTION, FREMANEZUMAB-VFRM, 1 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT SUPERVISION OF A PHYSICIAN, NOT FOR USE WHEN DRUG IS SELF-ADMINISTERED) |
Ajovy™ (fremanezumab-vfrm) |
12/02/2019 |
N/A |
Apparent on its Face |
J3110 |
INJECTION, TERIPARATIDE, 10 MCG |
Forteo® |
09/01/2006 |
N/A |
Apparent on its Face |
J3355 |
INJECTION, UROFOLLITROPIN, 75 IU |
Bravelle® |
10/31/2016 |
N/A |
Apparent on its Face |
J3357 |
USTEKINUMAB, FOR SUBCUTANEOUS INJECTION, 1 MG |
Stelara® (ustekinumab)
Subcutaneous
|
06/06/2022 |
N/A |
Acceptable Evidentiary Criteria Available |
J3490 |
UNCLASSIFIED DRUGS |
pegylated interferon alfa-2b) (PegIntron®) |
10/31/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Symlin® (Pramlintide Acetate Injection) |
10/31/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Somavert® (Pegvisomant) |
10/31/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
TriMix |
10/31/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Saxenda® (Liraglutide) |
10/31/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Exenatide extended release for injectable suspension Bydureon(™) |
08/06/2012 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Anakinra (Kineret™ 100 mg |
04/13/2003 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Exenatide injection (Byetta®) |
01/19/2006 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Golimumab (SIMPONI®) |
05/01/2010 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J3490 |
UNCLASSIFIED DRUGS |
Tesamorelin (Egrifta™) |
06/04/2011 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J3490 |
UNCLASSIFIED DRUGS |
Peginterferon alfa-2b (Sylatron ™) |
05/19/2012 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J3490 |
UNCLASSIFIED DRUGS |
Pasireotide (SIGNIFOR®) |
06/17/2013 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Parathyroid hormone (Natpara®) |
01/18/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Evolocumab (Repatha™) |
01/18/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Alirocumab (Praluent®) |
01/18/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
albiglutide for SQ injection (Tanzeum™) 30mg |
12/01/2014 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J3490 |
UNCLASSIFIED DRUGS |
Interferon beta 1a, 1 mcg (Rebif®) |
01/01/2014 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Liraglutide (VICTOZA®) |
05/01/2010 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Peginterferon alpha 2a (Pegasys®), Pegasys® Proclick™) |
03/05/2006 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Dulaglutide (Trulicity™) |
09/28/2015 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Methotrexate Injection (Otrexup™) |
09/28/2015 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Cosentyx® (secukinumab) |
09/28/2015 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Asfotase alfa (Strensiq™) |
05/23/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Myalept® Metreleptin for injection 11 mg
|
10/13/2014 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Toujeo® (Insulin glargine injection) |
10/31/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Plegridy® |
09/28/2015 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Taltz™ (Ixekizumab) |
10/31/2016 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Amjevita™ (adalimumab-atto) |
11/16/2017 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Dupixent® (dupilumab) |
11/16/2017 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Erelzi™ (etanercept-SZZS) |
11/16/2017 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Kynamro®, (Mipomersen sodium)
|
11/16/2017 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Tymlos™ (abaloparatide) |
12/02/2019 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Kevzara® (sarilumab) |
12/02/2019 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Ozempic® (semaglutide) |
12/02/2019 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Aimovig®
(erenumab-aooe)
|
12/02/2019 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Lantus® (insulin glargine injection) |
12/02/2019 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Emgality® (galcanezumab-gnlm) |
12/02/2019 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Cyltezo™
(adalimumab-adbm)
|
12/02/2019 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Quad-Mix |
11/16/2017 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Rasuvo® (methotrexate, injection for subcutaneous use) |
11/16/2017 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Siliq™ (brodalumab) |
11/16/2017 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Besremi® (ropeginterferon alfa-2b, injection for subcutaneous use) |
06/06/2022 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Skyrizi™ (risankizumab-rzaa, injection for subcutaneous use)* |
06/06/2022 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Sogroya® (Somapacitan-beco, injection for subcutaneous use) |
06/06/2022 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Kesimpta* (ofatumumab, injection for subcutaneous use) |
09/19/2022 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Adbry™ (tralokinumab-Idrm) |
11/14/2022 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Mounjaro™ (tirzepatide) |
03/27/2023 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
IDACIO® (adalimumab-aacf) |
06/25/2023 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
ABRILADA (adalimumab-afzb) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
HADLIMA (adalimumab-bwwd) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
HULIO® (adalimumab-fkjp) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
HYRIMOZ (adalimumab-adaz) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
YUSIMRY (adalimumab-aqvh) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Entyvio (vedolizumab) |
01/14/2024 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
YUFLYMA (adalimumab-aaty) |
01/14/2024 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Wegovy (Semaglutide) |
06/30/2024 |
N/A |
Apparent on its Face |
J3490 |
UNCLASSIFIED DRUGS |
Zepbound (Tirzepatide) |
06/30/2024 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Wegovy (Semaglutide) |
06/30/2024 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Zepbound (Tirzepatide) |
06/30/2024 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Entyvio (vedolizumab) |
01/14/2024 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
YUFLYMA (adalimumab-aaty) |
01/14/2024 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
IDACIO® (adalimumab-aacf) |
06/25/2023 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
ABRILADA (adalimumab-afzb) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
HADLIMA (adalimumab-bwwd) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
HULIO® (adalimumab-fkjp) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
HYRIMOZ (adalimumab-adaz) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
YUSIMRY (adalimumab-aqvh) is biosimilar to HUMIRA (adalimumab) |
06/25/2023 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Mounjaro™ (tirzepatide) |
03/27/2023 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Adbry™ (tralokinumab-Idrm) |
11/14/2022 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Kesimpta* (ofatumumab, injection for subcutaneous use) |
09/19/2022 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Besremi® (ropeginterferon alfa-2b, injection for subcutaneous use) |
06/06/2022 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Skyrizi™ (risankizumab-rzaa, injection for subcutaneous use)* |
06/06/2022 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Sogroya® (Somapacitan-beco, injection for subcutaneous use) |
06/06/2022 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Amjevita™ (adalimumab-atto) |
11/16/2017 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Dupixent® (dupilumab) |
11/16/2017 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Erelzi™ (etanercept-SZZS) |
11/16/2017 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Kynamro®, (Mipomersen sodium)
|
11/16/2017 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Quad-Mix |
11/16/2017 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Rasuvo® (methotrexate, injection for subcutaneous use) |
11/16/2017 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Siliq™ (brodalumab) |
11/16/2017 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Taltz™ (Ixekizumab) |
10/31/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Toujeo® (Insulin glargine injection) |
10/31/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Myalept® Metreleptin for injection 11 mg
|
10/13/2014 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
albiglutide for SQ injection (Tanzeum™) 30mg |
12/01/2014 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Interferon beta 1a, 1 mcg (Rebif®) |
01/01/2014 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Asfotase alfa (Strensiq™) |
05/23/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Anakinra (Kineret™) 100 mg |
04/13/2003 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Exenatide Injection (Byetta®) |
01/19/2006 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J3590 |
UNCLASSIFIED BIOLOGICS |
Golimumab (SIMPONI®) |
05/10/2010 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J3590 |
UNCLASSIFIED BIOLOGICS |
Dulaglutide (Trulicity™) |
09/28/2015 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Methotrexate Injection (Otrexup™) |
09/28/2015 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Peginterferon beta-1a (PLEGRIDY®) |
09/28/2015 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Cosentyx® (secukinumab) |
09/28/2015 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J3590 |
UNCLASSIFIED BIOLOGICS |
Tesamorelin (EgriftaTM) |
06/04/2011 |
N/A |
Presumption of Long-Term Non-Acute Administration |
J3590 |
UNCLASSIFIED BIOLOGICS |
Pasireotide (SIGNIFOR®) |
06/17/2013 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Alirocumab (Praluent®) |
01/16/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Evolocumab (Repatha™) |
01/18/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Parathyroid hormone (Natpara®) |
01/18/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Exenatide extended release for injectable suspension [Bydureon(™)] |
08/06/2012 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Peginterferon alpha 2a (Pegasys®), Pegasys® Proclick™) |
03/05/2006 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Liraglutide (VICTOZA®) |
05/01/2010 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Peginterferon alfa-2b (Sylatron™) |
05/19/2012 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Saxenda® (Liraglutide) |
10/31/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
TriMix |
10/31/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Somavert® (Pegvisomant) |
10/31/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Symlin® (Pramlintide Acetate Injection) |
10/31/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
pegylated interferon alfa-2b) (PegIntron®) |
10/31/2016 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Tymlos™ (abaloparatide) |
12/02/2019 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Kevzara® (sarilumab) |
12/02/2019 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Ozempic® (semaglutide) |
12/02/2019 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Aimovig® (erenumab-aooe) |
12/02/2019 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Lantus® (insulin glargine injection) |
12/02/2019 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Emgality® (galcanezumab-gnlm) |
12/02/2019 |
N/A |
Apparent on its Face |
J3590 |
UNCLASSIFIED BIOLOGICS |
Cyltezo™
(adalimumab-adbm)
|
12/02/2019 |
N/A |
Apparent on its Face |
J9212 |
INJECTION, INTERFERON ALFACON-1, RECOMBINANT, 1 MICROGRAM |
Infergen® |
10/31/2016 |
N/A |
Apparent on its Face |
J9213 |
INJECTION, INTERFERON, ALFA-2A, RECOMBINANT, 3 MILLION UNITS |
N/A |
10/31/2016 |
N/A |
Apparent on its Face |
J9216 |
INJECTION, INTERFERON, GAMMA 1-B, 3 MILLION UNITS |
Actimmune |
10/31/2016 |
N/A |
Apparent on its Face |
J9218 |
LEUPROLIDE ACETATE, PER 1 MG |
Lupron®, Eligard® |
12/20/1999 |
N/A |
Apparent on its Face |
Q0515 |
INJECTION, SERMORELIN ACETATE, 1 MICROGRAM |
N/A |
10/23/2016 |
N/A |
Apparent on its Face |
Q5131 |
INJECTION, ADALIMUMAB-AACF (IDACIO), BIOSIMILAR, 20 MG |
Idacio® injection |
09/03/2023 |
N/A |
Apparent on its Face |
Q5132 |
INJECTION, ADALIMUMAB-AFZB (ABRILADA), BIOSIMILAR, 10 MG |
Abrilada |
01/01/2024 |
N/A |
Apparent on its Face |
Q5137 |
INJECTION, USTEKINUMAB-AUUB (WEZLANA), BIOSIMILAR, SUBCUTANEOUS, 1 MG |
WEZLANATM (ustekinumab-auub) |
07/01/2024 |
N/A |
Apparent on its Face |